The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients

Diabetes, Obesity and Metabolism

Volumn 19, Issue 10, 2017, Pages 1363-1370

  Petrykiv, Sergei I ^a   Laverman, Gozewijn D ^b   de Zeeuw, Dick ^a   Heerspink, Hiddo J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TWENTEBORG HOSPITAL   (Netherlands)

Author keywords

albuminuria; dapagliflozin; response variability; SGLT2; type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; AGED; ALBUMINURIA; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; HYPOGLYCEMIA; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; ADOLESCENT; COMPLICATION; DIABETIC NEPHROPATHY; DRUG EFFECT; GLOMERULUS FILTRATION RATE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALBUMINURIA; BENZHYDRYL COMPOUNDS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; MALE; MIDDLE AGED; PLACEBOS; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85019905074     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12936     Document Type: Article

References (22)

1. Defronzo RA, Hompesch M, Kasichayanula S, et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36(10):3169-3176.
2. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223-2233.
3. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin: a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853-862.
4. Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjöström CD. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 2016;18:590-597.
5. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463-473.
6. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;2:369-384.
7. Cherney D, Lund SS, Perkins BA, et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59(9):1860-1870.
8. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.
9. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129:587-597.
10. Heerspink HJ, Perkins BA, Fitchett D, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications. Circulation. 2016;134(10):752-772.
11. Petrykiv SI, de Zeeuw D, Persson F, et al. Variability in response to albuminuria lowering drugs: true or random? Br J Clin Pharmacol. 2016. doi: 10.1111/bcp.13217
12. Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort R. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol. 2009;20:436-443.
13. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766-772.
14. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28:368-375.
15. Zobel EH, von Scholten BJ, Lindhardt M, Persson F, Hansen TW, Rossing P. Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: individual effects of treatment. J Diabetes Complications. 2017;31:162-168.
16. Holtkamp FA, de Zeeuw D, Thomas MC, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80:282-287.
17. Skrtic M, Yang GK, Perkins BA, et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014;57:2599-2602.
18. Kwakernaak AJ, Krikken JA, Binnenmars SH, et al. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol. 2013;2:385-395.
19. Navarro-Gonzalez JF, Mora-Fernandez C, Muros de Fuentes M, Garcia-Perez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011;7:327-340.
20. Kojima N, Williams JM, Takahashi T, Miyata N, Roman RJ. Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats. J Pharmacol Exp Ther. 2013;345:464-472.
21. Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS ONE. 2014;9:e100777.
22. Wanner C, Zinman B, Inzucchi SE, et al. Effect of empagliflozin on albuminuria in patients with type 2 diabetes at high cardiovascular risk. J Am Soc Nephrol. 2016;(suppl 1).